Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for Takeda GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

See Plans and Pricing

« Back to Dashboard

Takeda GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

Docket   Start Trial Date Filed 2015-05-27
Court District Court, N.D. West Virginia Date Terminated
Cause 35:271 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To
Patents 5,712,298; 8,431,154; 8,536,206; 8,604,064; 8,618,142
Attorneys Amy K. Wigmore; Christopher A. Lauderman; Dennis Gregory; Gordon H. Copland; James F. Companion; Mary Procaccio-Flowers; Nancy Zhang; Tracey C. Allen; Tung-On Kong; William J O'Brien; Yolonda G. Lambert
Firms Steptoe & Johnson PLLC - Bridgeport; Steptoe & Johnson, PLLC - Morgantown; Wilmer Cutler Pickering Hale & Dorr LLP; Wilson Sonsini Goodrich & Rosati
Link to Docket External link to docket
Small Molecule Drugs cited in Takeda GMBH v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Takeda GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-10-05 24 Plaintiffs’ U.S. Patent Nos. 5,712,298 (the “’298 patent”), 8,536,206 (the “’206 patent”), 8,604,064 (the…(the “’064 patent”), 8,618,142 (the “’142 patent”). Plaintiffs sell roflumilast tablets under the tradename…claims of the ’298, ’206, ’064, and ’142 patents, and that the patents are invalid. Additionally, Mylan has…Page 3 of 12 PageID #: 281 U.S. Patent No. 8,431,154 (the “’154 patent”), which, at present, has not been… ’206, ’064,’142, and ’154 patents are referred to herein as the “patents-in-suit.” External link to document
2015-10-09 26 #39;298 patent," as used herein, refers to and includes United States Patent No. 5,712,298, titled…combination of, or all of United States Patent Nos. 5,712,298, 8,431, 154, 8,536,206, 8,604,064, and …matter of the patents-in-suit or any patents or patent applications related to the patents-in-suit, and… The phrase "patents or patent applications related to the patents-in-suit" means every…enforcement or defense of any patent-in-suit or any related patent or patent application, and identification External link to document
2015-11-12 40 U.S. Patent No. 5,712,298 to reflect a patent term extension granted by the United States Patent and … Date of Expiration of Patents: • U.S. Patent No. 5,712,298: January 27, 2020 … Amended Supplemental Information for Patent Cases Involving An Abbreviated New Drug Application… AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG…hereby amend their “Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application External link to document
2015-11-23 45 of the patents-in-suit for deposition is as follows: • U.S. Patent No. 5.712«298; The sole… this patent, Dr. Hermann Amschler, is deceased. • U.S. Patent Nos. … • U.S. Patent No. 8.431.154; There are three named inventors on this patent, …three named inventors on these patents, all of whom reside in Germany: Mr. … 27 May 2015 1:15-cv-00093 830 Patent None District Court, N.D. West External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.